ArticleBMC cancer2025
Predictive value of androgen receptor in distant metastasis of triple-negative breast cancer: a retrospective multi-center study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough androgen receptor (AR) is highly expressed in triple-negative breast cancer (TNBC), but its role in predicting distant metastasis remains uncertain. This study aimed to investigate the association between AR expression and distant metastasis, including bone metastasis, in TNBC patients. MATERIALS AND
methodsWe retrospectively analyzed clinical and pathological data from TNBC patients treated at two cancer centers between January 2016 and December 2022. Only cases with AR expression assessed by immunohistochemistry were included. Differences in clinical characteristics, preoperative ultrasound findings, treatment regimens, immunohistochemical features, and lymph node status were compared between patients with and without distant metastases. Logistic regression was used to identify factors associated with metastasis.
resultsAmong 381 TNBC patients, 79 (20.7%) developed distant metastases. The AR-negative status was significantly more common in the metastasis group than in the non-metastatic group (65.8% vs. 48.7%, P = 0.0007). Similarly, AR negativity prevalence was higher among patients with bone-only or bone plus visceral metastases compared to those without metastasis (64.4% vs. 48.7%, P = 0.048). Multivariate analysis identified AR-negative status as an independent risk factor for distant metastasis (P = 0.008), while its association with bone metastasis was not statistically significant.
conclusionNegative AR expression in primary TNBC tumors may serve as a potential predictive marker for distant metastasis. Further research is needed to clarify its role in bone metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.